ZA200108414B - Akt nucleic acids, polypeptides, and uses thereof. - Google Patents

Akt nucleic acids, polypeptides, and uses thereof.

Info

Publication number
ZA200108414B
ZA200108414B ZA200108414A ZA200108414A ZA200108414B ZA 200108414 B ZA200108414 B ZA 200108414B ZA 200108414 A ZA200108414 A ZA 200108414A ZA 200108414 A ZA200108414 A ZA 200108414A ZA 200108414 B ZA200108414 B ZA 200108414B
Authority
ZA
South Africa
Prior art keywords
polypeptides
nucleic acids
akt3
akt nucleic
relates
Prior art date
Application number
ZA200108414A
Other languages
English (en)
Inventor
Kun Guo
Kenneth L Clark
Marco F Pagnoni
Yuri D Ivashchenko
Original Assignee
Aventis Pharm Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharm Prod Inc filed Critical Aventis Pharm Prod Inc
Publication of ZA200108414B publication Critical patent/ZA200108414B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
ZA200108414A 1999-03-19 2001-10-12 Akt nucleic acids, polypeptides, and uses thereof. ZA200108414B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12510899P 1999-03-19 1999-03-19

Publications (1)

Publication Number Publication Date
ZA200108414B true ZA200108414B (en) 2003-03-26

Family

ID=22418217

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200108414A ZA200108414B (en) 1999-03-19 2001-10-12 Akt nucleic acids, polypeptides, and uses thereof.

Country Status (18)

Country Link
EP (1) EP1144600B1 (da)
JP (1) JP4237945B2 (da)
KR (1) KR100700908B1 (da)
AT (1) ATE402995T1 (da)
AU (1) AU782448B2 (da)
BR (1) BR0009170A (da)
CA (1) CA2343074C (da)
CY (1) CY1108459T1 (da)
DE (1) DE60039677D1 (da)
DK (1) DK1144600T3 (da)
ES (1) ES2310515T3 (da)
HK (1) HK1041288B (da)
IL (4) IL141984A0 (da)
NO (1) NO20014537L (da)
PT (1) PT1144600E (da)
SI (1) SI1144600T1 (da)
WO (1) WO2000056866A2 (da)
ZA (1) ZA200108414B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6881555B2 (en) 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
HUP0200799A3 (en) 1999-04-16 2004-11-29 Univ Yale New Haven Enos mutations useful for gene therapy and therapeutic screening
KR20020012270A (ko) * 1999-06-11 2002-02-15 오흘러 로스 제이. 세린/트레오닌 단백질 키나제 ａｋｔ에 의한 혈관 내피세포 성장 인자(ｖｅｇｆ)의 유도
JPWO2003063905A1 (ja) * 2002-01-31 2005-05-26 株式会社東京大学Ｔｌｏ 免疫疾患の予防又は治療剤
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
EP1661581A1 (en) * 2003-07-28 2006-05-31 Osaka Industrial Promotion Organization Remedy for cardiac failure comprising ask1 inhibitor as the active ingredient and method of screening the same
EP2304439A4 (en) * 2008-05-29 2012-07-04 Nuclea Biotechnologies Llc ANTI-phospho-AKT ANTIBODY
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
PT2588475E (pt) 2010-07-02 2015-09-08 Gilead Sciences Inc Inibidores de cinase reguladora dos sinais da apoptose
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
BR112017005693A2 (pt) 2014-09-24 2017-12-12 Gilead Sciences Inc método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
CN107108519B (zh) 2014-12-23 2020-11-03 吉利德科学公司 制备ask1抑制剂的方法
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08109197A (ja) * 1994-10-07 1996-04-30 Sumitomo Electric Ind Ltd 白血病腫瘍拒絶抗原ペプチド
JP4173544B2 (ja) * 1995-11-16 2008-10-29 ノバルティス アクチエンゲゼルシャフト 治療剤としての、または診断におけるｒａｃ−プロテインキナーゼ
US5958773A (en) * 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
GB9828375D0 (en) * 1998-12-22 1999-02-17 Janssen Pharmaceutica Nv Human akt-3
US6043090A (en) * 1999-03-23 2000-03-28 Isis Pharmaceuticals Inc. Antisense inhibition of human Akt-2 expression
WO2000058473A2 (en) * 1999-03-31 2000-10-05 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; 'orfx'
KR20020012270A (ko) * 1999-06-11 2002-02-15 오흘러 로스 제이. 세린/트레오닌 단백질 키나제 ａｋｔ에 의한 혈관 내피세포 성장 인자(ｖｅｇｆ)의 유도

Also Published As

Publication number Publication date
DE60039677D1 (de) 2008-09-11
EP1144600A2 (en) 2001-10-17
EP1144600B1 (en) 2008-07-30
JP2002539781A (ja) 2002-11-26
PT1144600E (pt) 2008-10-10
KR100700908B1 (ko) 2007-03-29
BR0009170A (pt) 2002-04-30
JP4237945B2 (ja) 2009-03-11
SI1144600T1 (sl) 2008-12-31
AU3880200A (en) 2000-10-09
WO2000056866A9 (en) 2002-08-29
WO2000056866A2 (en) 2000-09-28
CY1108459T1 (el) 2013-09-04
IL190270A (en) 2012-12-31
CA2343074A1 (en) 2000-09-28
KR20020011972A (ko) 2002-02-09
HK1041288B (zh) 2008-11-07
AU782448B2 (en) 2005-07-28
WO2000056866A3 (en) 2001-02-15
CA2343074C (en) 2010-09-21
IL141984A0 (en) 2002-03-10
ES2310515T3 (es) 2009-01-16
HK1041288A1 (en) 2002-07-05
ATE402995T1 (de) 2008-08-15
IL145514A0 (en) 2002-06-30
NO20014537D0 (no) 2001-09-18
IL145514A (en) 2010-05-17
NO20014537L (no) 2001-10-31
DK1144600T3 (da) 2008-11-24

Similar Documents

Publication Publication Date Title
CY1108459T1 (el) Ακτ-3 νουκλεϊκα οξεα, πολυπεπτιδια, και χρησεις αυτων
WO2003103589A3 (en) USE OF IL-21 IN THE TREATMENT OF CANCER AND OTHER THERAPEUTIC APPLICATIONS
NZ502392A (en) Interleukin-18 binding proteins (IL-18BP) their preparation and use in pharmaceuticals
WO2000055345A3 (en) Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
MX344216B (es) Productos geneticos expresados de forma diferencial en tumores y su uso.
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
PL308122A1 (en) Viral vectors and their application in genic therapy
WO2001034641A3 (en) Antimicrobial activity of the first cationic cluster of human lactoferrin
MXPA04001720A (es) Acido nucleicos bv8 y polipeptidos con actividad mitogenica.
IL174645A0 (en) MODIFIED cDNA FOR HIGH EXPRESSION LEVELS OF FACTOR VIII AND ITS DERIVATIVES
HK1052026A1 (en) Human enzymes of the metalloprotease family
NZ516237A (en) Meth1 and meth2 polynucleotides and polypeptides
EE200000102A (et) Meetodid ja kompositsioonid teraapiaks, kasutades sekreteeritavaid valke, näiteks interferoon-beetat kodeerivaid geene
UA84831C2 (ru) Производные фактора коагуляции vii
WO2001077338A3 (en) Human protein kinases and protein kinase-like enzymes
WO2003070878A3 (en) Antisense modulation of hematopoietic cell protein tyrosine kinase expression
WO2002014369A3 (en) Human kininogen d5 domain polypeptides and their use
ATE466588T1 (de) Bakteriophagen- und prophagen-proteine in der krebsgentherapie
AU2002246455A1 (en) Fusion proteins for specific treatment of cancer and auto-immune diseases
HUP0300813A2 (hu) Gének, fehérjék és alkalmazásuk
DE60034874D1 (de) Interne ribosom eintrittstelle (ires), vektor der diesen enthaltet und dessen therapeutische verwendung
PL370854A1 (en) Ee3-protein family and corresponding dna sequences
DE59805112D1 (de) Chimäre oligonucleotide und ihre verwendung